

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-165) PENPULIMAB

PRONUNCIATION pen pul' i mab

THERAPEUTIC CLAIM Antineoplastic

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human programmed cell death 1) (human-Mus musculus monoclonal AK105 γ 1-chain), disulfide with human-Mus musculus monoclonal AK105 κ -chain, dimer (Source: CAS)
2. Immunoglobulin G1-kappa, anti-[*Homo sapiens* PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], monoclonal antibody; gamma1 heavy chain (1-448) [VH (*Homo sapiens* IGHV3-23*04 (88.7%) -(IGHD) -IGHJ6*01 (90.9%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1-118) -*Homo sapiens* IGHG1*01 G1m17,1, G1v14 CH2 A1.3, A1.2 (CH1 K120 (215) (119-216), hinge 1-15 (217-231), CH2 L1.3>A (235), L1.2>A (236), G1>A (238) (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-214')-disulfide with kappa light chain (1'-214') [V-KAPPA (*Mus musculus* IGKV14-111*01 (86.3%) -IGKJ5*01 (100%)/*Homo sapiens* IGKV1-16*01 (80%) -IGKJ2*01 (81.8%) CDRIMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (227-227":230-230")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa (Source: WHO pINN list 123)

STRUCTURAL FORMULA

Heavy chain

EVQLVESGGG	LVQPGGSLRL	SCAASGFAPF	SYDMSWVRQA	PGKGLDWVAT	50
ISGGGRYTTY	PDSVKGRFTI	SRDNSKNNLY	LQMNSLRAED	TALYYCANRY	100
GEAWFAYWQ	GTLVTVSSAS	TKGPSVFPLA	PSSKSTSGGT	AALGCLVKDY	150
FPEPVTWSN	SGALTSGVHT	FPAVLQSSGL	YSLSSVVTVP	SSSLGTQTYI	200
CNVNHKPSNT	KVDKKVEPKS	CDKTHTCP	PAPEAAGAPS	VFLFPPKPKD	250
TLMISRTP	TCVVVDVSH	DPEVKFNWYV	DGVEVHNAKT	KPREEQYNST	300
YRVVSVLTVL	HQDWLNGKEY	KCKVSNKALP	APIEKTISKA	KGQPREPQVY	350
TLPPSRDEL	KNQVSLTCLV	KGFYPSDIAV	EWESNGQPEN	NYKTTTPVLD	400
SDGSFFLYSK	LTVDKSRWQQ	GNVVFSCVMH	EALHNHYTQK	SLSLSPGK	448

Light chain

DIQMTQSPSS	MSASVGDRVT	FTCRASQDIN	TYLSWFQQKP	GKSPKTLIYR	50
ANRLVSGVPS	RFSGSGSGQD	YTLTISLQ	EDMATYYCLQ	YDEFPLTFGA	100
GTKLELKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNIFY	PREAKVQWKV	150
DNALQSGNSQ	ESVTEQDSKD	STYLSSTLT	LSKADYEKHK	VYACEVTHQG	200
LSSPVTKSFN	RGEC				214

Disulfide bridges

22-96	22'-96''	23'-88'	23'''-88'''	134'-194'	134'''-194'''	145-201	145''-201''
221-214'	221'''-214'''	227-227''	230-230''	262-322	262'''-322'''	368-426	368''-426''

Glycosylation sites (N)

298	298''
-----	-------

MOLECULAR FORMULA	C ₆₄₃₄ H ₉₉₂₂ N ₁₇₁₈ O ₂₀₁₂ S ₄₆
MOLECULAR WEIGHT	145.0 kDa
TRADEMARK	None as yet
SPONSOR	Akeso Biopharma Co., Ltd.
CODE DESIGNATIONS	AK105
<u>CAS</u> REGISTRY NUMBER	2350298-92-7
UNII	IBS1BZ4E4I
WHO NUMBER	11497

gbk